Survival

ASCO: Selpercatinib Improves Event-Free Survival in RET Fusion-Positive NSCLC

Physician’s Briefing

ASCO: Selpercatinib Improves Event-Free Survival in RET Fusion-Positive NSCLC

3 hours ago

2 min read

ASCO: Intismeran Plus Pembrolizumab Ups RFS, DMFS in High-Risk Melanoma

Physician’s Briefing

ASCO: Intismeran Plus Pembrolizumab Ups RFS, DMFS in High-Risk Melanoma

01 Jun 2026

2 min read

ASCO: Daraxonrasib Effective for Metastatic Pancreatic Ductal Adenocarcinoma

Physician’s Briefing

ASCO: Daraxonrasib Effective for Metastatic Pancreatic Ductal Adenocarcinoma

01 Jun 2026

2 min read

Read More

Clinical Briefing Report

clinicalbriefingreport.com